menu-hamburger-svgrepo-com

WEBINAR REPLAY

Replay available: Understanding and managing bipolar depression and mixed mood states

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Presented by

:
:
DAYS
HRS
MINS

BOOKINGS

cocoa-gb99a1b92d_1280

Overview of main concepts related to bipolar disorder

Bipolar disorder affects 2.8 % of the adult population. Bipolar I affect men and women equally while bipolar II affects more women than men. Age of onset is late adolescence or early adulthood. The average time to correct diagnosis is 10 years. It is a chronic illness with remissions and exacerbations even on medication (50% of the time the patient is unwell).

  • Bipolar II more time ‘unwell’
  • Bipolar II – predominant mood state is depression
  • Bipolar I more time hypomanic/manic than Bipolar II
  • 60% of patients have significant and chronic interpersonal and occupational difficulties
  • Completed suicide rate is ~10 %
  • Suicide attempts: 30%-50%
  • Increased risk of suicide attempts in mixed depressive states.

Screening tool

WHIPLASHED screening tool for bipolar depression or the presence of bipolarity
and assists to differentiate bipolar from unipolar depression:

W - Worse or ‘wired’ when taking antidepressants. Failed trials. Switching on AD

H  - Hypomania, hyperthymic temperament

I    - Irritability and mixed features during the presenting episode of depression

P  - Psychomotor retardation

L - Loaded family history

A - Abrupt onset and/or termination of depressive bouts

S - Seasonal or postpartum pattern of depression

H - Hyperphagia and hypersomnia

E - Early age at depression onset (younger than 25 years)

D - Delusions, hallucinations, or other psychotic features appear to be more common in bipolar disorder.

Making a diagnosis of a bipolar mixed mood state

Types of mixed states:

  • Depressed type with hypomanic/manic features
  • Hypomanic/manic type with depressed features.Risk of untreated bipolar depressive or mixed states:
  • High risk of suicidal ideation (>70% attempts) during mixed and depressed episodes of bipolar disorder
  • Mixed episodes are particularly high risk for suicide attempts
  • Overdose is the most common method of suicide (caution with certain medications)
  • Significant functional and cognitive impairment is associated with untreated lengthy episodes of bipolar disorder.

Management of bipolar depression and mixed mood states

Follow the general treatment principles and assess:

  • Medication status
  • Risk
  • Setting of treatment
  • Laboratory investigations
  • Substance use
  • Past response to agents
  • Recent discontinuation of agents
  • Consider ECT (suicide risk, psychotic depression, catatonic).

First-line agents for bipolar depression

Monotherapy: Quetiapine 300-600mg (evidence for 150 mg +)

Lithium (target 0.8-1.2meq/l)

Lamotrigine (target >200mg – need to go up slowly 25mg every two weeks).

Adjunct agents:

  • Quetiapine
  • Lithium
  • Lamotrigine

If depressed on an antidepressant, switch or stop the antidepressant (be careful with venlafaxine), taper and cross-titrate.

  • Alternative first-line agent/second-line treatments. Don’t switch lamotrigine as it needs time to work
  • Add on or switch treatment – second line agents
  • Monotherapy – valproate
  • SSRI (adjunct)
  • Bupropion (adjunct)
  • Olanzapine + fluoxetine
  • Monotherapy – valproate.

Alternative third-line treatment:

  • Aripiprazole (adjunct)
  • Carbamazepine (mono)
  • Ketamine IV (adjunct)
  • Levothyroxine (adjunct)
  • Olanzapine (mono).

Agents not recommended for treatment of bipolar depression:

  • Antidepressant monotherapy
  • Aripiprazole monotherapy
  • Ziprasidone monotherapy
  • Gabapentin
  • Risperidone.

Expert consensus

According to the International Society for Bipolar Disorders (ISBD) Antidepressant Task Force recommendations for the use of antidepressants in bipolar depression: Mood stabilisers or atypical antipsychotics should be considered as first-line treatment for bipolar depression.

Antidepressants should be used with caution in bipolar depression, especially in patients with a history of switching to mania or hypomania during antidepressant treatment. The potential risks and benefits of antidepressant treatment should be considered in individual patients.

Patients should be closely monitored for manic or hypomanic symptoms during antidepressant treatment, particularly during the first few weeks or after dosage adjustments. A low-dose antidepressant in combination with a mood stabiliser or atypical antipsychotic may be considered instead of using an antidepressant as monotherapy. Antidepressant treatment should be discontinued in patients who do not respond adequately after four-six weeks, or who experience significant adverse effects or switch to mania or hypomania.

Non-pharmacological interventions such as psychotherapy or light therapy may be considered adjunctive treatment for bipolar depression.

Pharmacological treatment of mixed episodes

Distinguish mixed states from both mania and agitated depression. Taper and cease medications with mood elevating properties, especially those that may induce inter-episode switching. Antidepressants can worsen or induce rapid cycling and are thus not recommended. Lithium may have reduced efficacy for treating mixed states.

Treatment options include:

  • Olanzapine
  • Quetiapine or valproate as monotherapy
  • Olanzapine and fluoxetine in combination
  • Valproate in combination with olanzapine.

Important discussions with your patient

  • Adherence
  • Collaborative, understanding reasons for non-adherence, 50% non-adherence rate
  • Educate on side effects
  • Educate on treatment withdrawal – 50-90% of lithium withdrawal relapse within five months
  • Risks for suicide and development of mixed mood states
  • Management of comorbidities.

 

CLICK HERE TO VIEW A REPLAY OF THIS WEBINAR

Sign in to access full articles and earn your CPD points.

Clinical and CPD content is compiled by Key Opinion Leaders and our expert medical editors.

Already registered? Login here

Past webinars

Suggested clinical & CPD content

Related articles

idea

1000’s of Clinical and CPD content compiled by Key Opinion Leaders and our expert medical editors.

connection

Access to medical webinars and events

Group 193

Access medical journals from industry leaders and expert medical editorials.

Congratulations! Your account was successfully created.

Please check your email for an activation mail. Click the activation link to activate your account

Stay up to date

Search for anything across CPD, webinars and journals
idea

1000’s of Clinical and CPD content compiled by Key Opinion Leaders and our expert medical editors.

connection

Access to medical webinars and events

Group 193

Access medical journals from industry leaders and expert medical editorials.

Congratulations! You have successfully booked your seat.

All webinar details will be emailed to your email address.

Did you know, you can book future webinars with a single click if you register an account with Medical Academic.

Congratulations! Your account was successfully created.

Your webinar seat has been booked and all webinar details will be emailed to your registered email address

Why not register for Medical Academic while booking your seat for this webinar?

Future Medical Academic webinars can be booked with a single click, all with a Medical Academic account… and it’s FREE.

Book webinar & create your account

* (Required)

idea

1000’s of Clinical and CPD content compiled by Key Opinion Leaders and our expert medical editors.

connection

Access to medical webinars and events

Group 193

Access medical journals from industry leaders and expert medical editorials.

Congratulations! Your account was successfully created.

Thank you for registering. You can now log in to your account.

Create your account

* (Required)

Login with One Time Pin (OTP)

Enter your registered email address to receive an OTP

A verification code will be sent to your email address. Please ensure that admin@medicalacademic.co.za is on your safe sender list.

We've sent your OTP
Welcome to Medical Academic​

Get the most out of Medical Academic by telling us your occupation. This helps us create more great content for you and the community.